2019
-
November 06, 2019 Pharmaceuticals PDF431 KB
-
November 06, 2019 Management & Finance
Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2019
-
October 07, 2019 Pharmaceuticals PDF310 KB
-
October 07, 2019 Pharmaceuticals PDF282 KB
-
October 02, 2019 Pharmaceuticals PDF220 KB
(Media)U.S. FDA Submission of New Drug Application for NS-065/NCNP-01 (viltolarsen)
-
September 26, 2019 Pharmaceuticals PDF241 KB
(Media)Submission of New Drug Application for NS-065/NCNP-01 (viltolarsen) in Japan
-
September 04, 2019 Pharmaceuticals PDF265 KB
-
August 22, 2019 R & D PDF239 KB
(Media)NS-065/NCNP-01 (viltolarsen) under development, granted Orphan Drug Designation by MHLW
-
August 07, 2019 Management & Finance
Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2019
-
June 18, 2019 Pharmaceuticals PDF176 KB
-
May 24, 2019 Management & Finance PDF2 MB
Presentation Material for 6th Five-Year Medium-term Management Plan
-
May 22, 2019 Pharmaceuticals PDF223 KB
(Media)Launch of ERLEADA® (apalutamide) 60mg tablet for the treatment of prostate cancer
-
May 14, 2019 Management & Finance PDF135 KB
-
May 13, 2019 Management & Finance
Outline of Consolidated Financial Results for the Year Ended March 31, 2019
-
May 10, 2019 Management & Finance PDF34 KB
(Media)Notification of a Contract Concluded for Tadalafil, a Phosphodiesterase-5 Inhibitor
-
April 23, 2019 Management & Finance PDF55 KB
-
March 26, 2019 Pharmaceuticals PDF168 KB
-
March 25, 2019 Pharmaceuticals PDF100 KB
(Media)Results of the PHOSPHASE study of iron isomaltoside 1000 in ENDO congress
-
March 19, 2019 Corporate PDF142 KB
(Media)Exclusive Distribution Agreement with Zogenix for ZX008 in Japan
-
February 06, 2019 Management & Finance
Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2018
-
January 21, 2019 Corporate PDF103 KB
(Media) Nippon Shinyaku Co., LTD. signs co-promotion agreement with Janssen for apalutamide